Cardoso F - Search Results

1

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.

Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C. Galmarini CM, et al. Among authors: cardoso f. Clin Cancer Res. 2008 Jul 15;14(14):4511-6. doi: 10.1158/1078-0432.CCR-07-4741. Clin Cancer Res. 2008. PMID: 18628466 Clinical Trial.

2

3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.

Ferreira Filho AF, Crown J, Cardoso F, Nogaret JM, Duffy K, Dolci S, Rowan S, O'Higgins N, Batter V, Paesmans M, Piccart MJ, Di Leo A. Ferreira Filho AF, et al. Among authors: cardoso f. Anticancer Res. 2002 Jul-Aug;22(4):2471-6. Anticancer Res. 2002. PMID: 12174946 Clinical Trial.

3

HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.

Larsimont D, Di Leo A, Rouas G, Paesmans M, Ferreira-Filho F, Bernard C, Cardoso F, Verhest A, Piccart MJ, Gancberg D. Larsimont D, et al. Among authors: cardoso f. Anticancer Res. 2002 Jul-Aug;22(4):2485-90. Anticancer Res. 2002. PMID: 12174949

4

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.

Gancberg D, Järvinen T, di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J, Larsimont D. Gancberg D, et al. Among authors: cardoso f. Breast Cancer Res Treat. 2002 Jul;74(2):113-20. doi: 10.1023/a:1016146130767. Breast Cancer Res Treat. 2002. PMID: 12186371

5

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

Di Leo A, Cardoso F, Durbecq V, Giuliani R, Mano M, Atalay G, Larsimont D, Sotiriou C, Biganzoli L, Piccart MJ. Di Leo A, et al. Among authors: cardoso f. Int J Clin Oncol. 2002 Aug;7(4):245-53. doi: 10.1007/s101470200036. Int J Clin Oncol. 2002. PMID: 12202978 Review.

6

Resistance to trastuzumab: a necessary evil or a temporary challenge?

Cardoso F, Piccart MJ, Durbecq V, Di Leo A. Cardoso F, et al. Clin Breast Cancer. 2002 Oct;3(4):247-57; discussion 258-9. doi: 10.3816/CBC.2002.n.028. Clin Breast Cancer. 2002. PMID: 12425752 Review.

7

Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.

Cardoso F, Di Leo A, Piccart MJ. Cardoso F, et al. Cancer Treat Rev. 2002 Dec;28(6):275-90. doi: 10.1016/s0305-7372(02)00091-9. Cancer Treat Rev. 2002. PMID: 12470979 Review.

8

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.

Bernard-Marty C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A. Bernard-Marty C, et al. Among authors: cardoso f. Clin Breast Cancer. 2002 Dec;3(5):341-5. doi: 10.3816/CBC.2002.n.037. Clin Breast Cancer. 2002. PMID: 12533264

9

[News in the medical treatment of breast cancer].

Piccart M, Dochy E, Cardoso F. Piccart M, et al. Among authors: cardoso f. Bull Cancer. 2003 Jan;90(1):46-52. Bull Cancer. 2003. PMID: 12609804 Free article. Review. French.

10

Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer.

Cardoso F, Lohrisch C, Piccart MJ. Cardoso F, et al. Drugs Today (Barc). 2003 Jun;39(6):399-414. doi: 10.1358/dot.2003.39.6.799447. Drugs Today (Barc). 2003. PMID: 12944994 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,465 results

Search Page

Filters